Key Highlights
● Board approved a quarterly Dividend of $0.5158 per share, payable 15 January 2027
● Fiscal first-quarter non-GAAP EPS rose 27.8% to $3.26, well ahead of consensus
● Full-year non-GAAP EPS guidance raised to $12.80 to $13.00
● Binding letter of intent with CVS Health would renew the relationship through June 2032
Why did Cardinal Health (NYSE:CAH) keep inching higher on Wednesday, 11 November 2026? The drug and medical-products distributor finished the session at about $277.45, up roughly 0.2% (about 66 cents) from Tuesday's $276.79 close, on a day when the board approved the next quarterly dividend and Wall Street was still digesting a strong beat-and-raise quarter from the previous week. The gain was modest, but it extended a run that has taken the stock up close to 6% since its $261.93 close on 4 November, the last session before the results.
The move and its catalyst
The only fresh company news on Wednesday was routine. Cardinal Health said its board approved a quarterly dividend of $0.5158 per share, payable on 15 January 2027 to shareholders of record on 4 January 2027. That keeps the payout unchanged and is not the kind of announcement that usually moves a $60-billion-plus company much, which is consistent with the small gain.
The bigger driver of recent trading is the fiscal first-quarter 2027 report published on 5 November. Cardinal posted non-GAAP Earnings of $3.26 per share, up 27.8% from a year earlier and well ahead of the roughly $2.92 consensus. Revenue rose 5.5% to $67.51 billion, slightly above expectations, and non-GAAP operating earnings reached a record of about $1.0 billion. Management raised its full-year non-GAAP EPS guidance by $0.40 at the midpoint, to $12.80 to $13.00. It also disclosed a binding letter of intent with CVS Health (NYSE:CVS) that would renew that relationship through June 2032.
Analysts followed with higher targets. UBS lifted its price target to $310 from $295 and kept a Buy rating, TD Cowen raised its target to $304 from $280, and JPMorgan moved to $286 from $260 while staying at Neutral. Those revisions, rather than anything new on Wednesday, explain why the shares have held their post-earnings gains.
The wider market helped at the margin. The S&P 500 rose 1.3% on Wednesday, led by technology and a rebound in AI-linked chip stocks. Health care was close to flat for the day, up only about 0.04% according to a closing sector tally, so Cardinal's small rise was roughly in line with its sector rather than a standout.
What Cardinal Health does
Cardinal Health is one of the three large US pharmaceutical wholesalers. It buys branded, generic and specialty drugs from manufacturers and delivers them to retail pharmacies, hospitals and clinics. Its Pharmaceutical and Specialty Solutions segment produces most of the revenue and profit. In the latest quarter that segment's profit rose 17% to $783 million, and specialty products grew 18%. A smaller Global Medical Products and Distribution (GMPD) arm makes and distributes medical and surgical supplies. A group of "Other" businesses, including nuclear pharmacy, at-home solutions and the OptiFreight logistics platform, earns much higher margins: profit there rose 16% to $193 million, a Margin of about 11%.
Why its revenue per employee is so high
Cardinal ranks 61st among US companies with the highest revenue per employee, at about $3.98 million per worker on a fiscal-year basis. With roughly 63,900 employees, the company books well over $250 billion a year in sales.
That figure comes from how drug distribution works. Cardinal books the full price of the medicines it moves, including expensive branded and specialty drugs, as revenue, even though it keeps only a thin slice. Pharma segment margin was about 1.25% last quarter. Highly automated distribution centres let a relatively small workforce handle enormous dollar volumes. The other side of this is that revenue per head says little about profitability. The Economics depend on scale, purchasing Leverage with generic manufacturers, and keeping operating costs tight against razor-thin margins.
Financials and valuation
The quarter was strong. GAAP EPS rose 27% to $2.38, a figure that included a $47 million litigation recovery excluded from non-GAAP results. Operating Cash Flow was about $1.4 billion. Part of the EPS growth came from below the operating line: a lower non-GAAP tax rate (18.5% versus 21.9%) and a smaller diluted share count (233 million versus 239 million) after a $500 million accelerated buyback. Management guided fiscal 2027 free cash flow to $3.5 billion to $4.0 billion, below the roughly $5 billion delivered in fiscal 2026.
At about $277, the stock trades around 21.5 times the midpoint of the new EPS guidance. Market data puts the trailing GAAP P/E in the mid-30s, inflated by past charges. The dividend yields only about 0.7%, but the company has 29 consecutive years of increases. Market Capitalisation is in the low-to-mid $60 billion range. The analyst consensus is "Moderate Buy," with 16 Buy and 3 Hold ratings.
Sector context and risks
Drug distributors have been steady performers because prescription volumes, specialty drugs and GLP-1 obesity and diabetes treatments keep pushing dollar throughput higher. Policy is the biggest swing factor. Cardinal's guidance assumes roughly a 400-basis-point drag on pharma revenue growth from Inflation Reduction Act drug-price negotiations. Management has not quantified possible 340B and hospital outpatient payment changes, and it continues to disclose Department of Justice investigations.
The GMPD segment is the clear weak spot. Its profit fell 28% to $33 million on flat $3.2 billion revenue, hit by distribution volumes, foreign exchange and high petroleum-based input costs. With Brent Crude above $92 a barrel on Wednesday amid Middle East Supply concerns, resin and freight costs remain a live risk. Management now expects GMPD to land near the low end of its $200 million to $220 million profit range. It has also said pharma earnings growth should moderate in the second and third quarters, partly because comparisons get harder.
Valuation is the final risk. After a run from a late-September low of about $216.70, much good news is priced in, and the consensus target is only modestly above the current price. Macro conditions matter too: Tuesday's hotter-than-expected inflation report pushed Treasury yields higher, and futures markets are pricing in Federal Reserve rate hikes. That backdrop tends to weigh on richly valued defensive stocks.
CVS Deal and February Test
Investors will watch for the CVS letter of intent to become a definitive agreement, and for any update on renewal of the Red Oak generics sourcing venture. Regulatory headlines on drug pricing, 340B and outpatient reimbursement are likely to drive day-to-day moves. Further progress in specialty pharmaceuticals will show whether the higher-margin businesses can keep growing. That includes Cardinal's third exclusive cell and gene therapy third-party logistics agreement and a planned St. Louis cold-chain facility. The fiscal second-quarter report, expected around early February, will be the next real test of whether the raised $12.80 to $13.00 EPS outlook holds as pharma growth slows.






Please wait processing your request...